ConductScience.org, home

Paper40282924

Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.

Vruzhaj I and 5 others. Medicina (Kaunas), 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Papers, record 40282924. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40282924

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.
PubMed
Journal
Medicina (Kaunas)
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.65, provisional
iCite
Revised in PubMed
2025-04-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GlypicansMajor topic
Pancreatic NeoplasmsMajor topic
Escherichia coliMajor topic
ImmunotherapyMajor topic
Gastrointestinal MicrobiomeMajor topic
Animals
Mice
Administration, Oral
Humans
Cancer Vaccines
Cell Line, Tumor
Carcinoma, Pancreatic Ductal

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
PNRR-M4C2-I1
The research leading to these results has received funding from the European Un-ion-NextGenerationEU through the Italian Ministry of University and Research under PNRR-M4C2-I1.3 Project PE_00000019 "HEAL ITALIA" to Giuseppe Toffoli (Spoke 6) (CUP J33C2200
PubMed

Source PubMed

Download CSV of grants

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136839825Recent Advances in Cancer Immunotherapy Delivery Modalities.Pharmaceutics2023https://conductscience.org/library/papers/36839825PubMed
225276427Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.Mol Biol Int2014https://conductscience.org/library/papers/25276427PubMed
334063669B Cells and Microbiota in Autoimmunity.Int J Mol Sci2021https://conductscience.org/library/papers/34063669PubMed
414734740Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC.J Immunol2004https://conductscience.org/library/papers/14734740PubMed
536804602Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention.Gastroenterology2023https://conductscience.org/library/papers/36804602PubMed
615767015Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo.J Microbiol Methods2005https://conductscience.org/library/papers/15767015PubMed
734616044Metabolic modulation of tumours with engineered bacteria for immunotherapy.Nature2021https://conductscience.org/library/papers/34616044PubMed
834328099Emerging roles of miRNAs in the development of pancreatic cancer.Biomed Pharmacother2021https://conductscience.org/library/papers/34328099PubMed
934583978Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.Mol Cancer Ther2021https://conductscience.org/library/papers/34583978PubMed
1015489184Let's go mucosal: communication on slippery ground.Trends Immunol2004https://conductscience.org/library/papers/15489184PubMed
1128233802Targeting neoantigens to augment antitumour immunity.Nat Rev Cancer2017https://conductscience.org/library/papers/28233802PubMed
1216581299Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination.Mol Ther2006https://conductscience.org/library/papers/16581299PubMed
1315141160Potential therapeutic applications of recombinant, invasive E. coli.Gene Ther2004https://conductscience.org/library/papers/15141160PubMed
1412219778Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli.Am J Clin Pathol2002https://conductscience.org/library/papers/12219778PubMed
1537631987Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective.Viruses2023https://conductscience.org/library/papers/37631987PubMed
1618064304Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.J Clin Invest2008https://conductscience.org/library/papers/18064304PubMed
1727640192Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application.Appl Microbiol Biotechnol2016https://conductscience.org/library/papers/27640192PubMed
1811471563Genetic modification of intestinal lactobacilli and bifidobacteria.Curr Issues Mol Biol2000https://conductscience.org/library/papers/11471563PubMed
1928440066Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.Cancer Med2017https://conductscience.org/library/papers/28440066PubMed
2028299466Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.Cancer Immunol Immunother2017https://conductscience.org/library/papers/28299466PubMed

See all 57 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42346015The Gut Microbiome Dependency Continuum in Drug Discovery: A Unified Pharmacology Framework Linking Clinical Drugs, Natural Products, and Engineered Microbial Therapeutics.BioTech (Basel)2026https://conductscience.org/library/papers/42346015PubMed
41228299Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer.Cancers (Basel)2025https://conductscience.org/library/papers/41228299PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40282924

GET https://conductscience.org/api/papers/v1/40282924/references?page=2